Clinical trials in Sevilla

1 628 clinical trials in Sevilla, Spain across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in SpainEnsayosClinicos.es

Sevilla at a glance

1 628

clinical trials

Research sites4

Quick filters

1 628 trials in Sevilla

Open in trial search

Sjogren's syndrome

Recruiting

Phase 3 Randomized, Double‑Blind Study of Telitacicept versus Placebo for Efficacy and Safety in Adults with Active Primary Sjögren’s Disease

Investigational

Phase 3 Randomized, Double‑Blind Study of Telitacicept versus Placebo for Efficacy and Safety in Adults with Active Primary Sjögren’s Disease

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:Telitacicept
Sponsor:Vor Biopharma Inc.

Contact Research Centre

Immunisation+3

Recruiting

SARS‑CoV‑2 spike protein vaccine and drug combination study in adults 60 years and older with COVID‑19 and influenza

Registered drug

SARS‑CoV‑2 spike protein vaccine and drug combination study in adults 60 years and older with COVID‑19 and influenza

Registered drug

Spain

Participants:18–64 years · 65+ years · Healthy volunteers
Substances:INFLUENZA A VIRUS, A/CROATIA/10136RV/2023 (H3N2) LIKE STRAIN X-425A, INACTIVATED
Sponsor:Sanofi Pasteur Inc.

Contact Research Centre

Type 2 diabetes mellitus+2

Recruiting

Effect of lenbelintide (AZD6234) on body weight in adults with type 2 diabetes and obesity or overweight

Investigational

Effect of lenbelintide (AZD6234) on body weight in adults with type 2 diabetes and obesity or overweight

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:AZD6234
Sponsor:AstraZeneca AB

Contact Research Centre

Dermatitis atopic

Recruiting

Efficacy and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Face and Neck Atopic Dermatitis

Registered drug

Efficacy and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Face and Neck Atopic Dermatitis

Registered drug

Spain

Participants:0–17 years · 18–64 years · 65+ years
Substances:Lebrikizumab
Sponsor:Almirall S.A.

Contact Research Centre

Obesity+1

Recruiting

Phase 3 Extension Trial Evaluating Long‑Term Efficacy, Safety and Tolerability of maridebart cafraglutide in Adults with Obesity

Investigational

Phase 3 Extension Trial Evaluating Long‑Term Efficacy, Safety and Tolerability of maridebart cafraglutide in Adults with Obesity

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:Maridebart Cafraglutide
Sponsor:Amgen Inc.

Contact Research Centre

Pancreatic carcinoma metastatic

Recruiting

Phase 3 Study of atebimetinib with gemcitabine and paclitaxel versus gemcitabine and paclitaxel in patients with metastatic pancreatic cancer

Registered drugNo placebo

Phase 3 Study of atebimetinib with gemcitabine and paclitaxel versus gemcitabine and paclitaxel in patients with metastatic pancreatic cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Atebimetinib
Sponsor:Immuneering Corp.

Contact Research Centre

Obesity+2

Recruiting

Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease

Investigational

Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease

Investigational

Spain

Participants:18–64 years
Substances:Zenagamtide
Sponsor:Novo Nordisk A/S

Contact Research Centre

Narcolepsy

Recruiting

Phase 3 Study of Pitolisant for Excessive Daytime Sleepiness in Narcolepsy Patients

Investigational

Phase 3 Study of Pitolisant for Excessive Daytime Sleepiness in Narcolepsy Patients

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:Pitolisant
Sponsor:Harmony Biosciences Management Inc.

Contact Research Centre

Major depression

Recruiting

Study of Brenipatide (LY3537031) in Adults with Major Depressive Disorder to Evaluate Delay of Relapse Compared with Placebo

Investigational

Study of Brenipatide (LY3537031) in Adults with Major Depressive Disorder to Evaluate Delay of Relapse Compared with Placebo

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:LY3537031
Sponsor:Eli Lilly & Co.

Contact Research Centre

Ocular myasthenia

Recruiting

A Phase 3 Randomized Study of Rozanolixizumab for Safety and Efficacy in Adults with Ocular Myasthenia Gravis

Registered drug

A Phase 3 Randomized Study of Rozanolixizumab for Safety and Efficacy in Adults with Ocular Myasthenia Gravis

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:Rozanolixizumab
Sponsor:UCB Biopharma

Contact Research Centre

Graves' disease

Recruiting

Phase 3 Randomized Placebo‑Controlled Study of Efgartigimod Alfa in Adults with Graves’ Disease Inadequately Controlled by Antithyroid Drugs

Registered drug

Phase 3 Randomized Placebo‑Controlled Study of Efgartigimod Alfa in Adults with Graves’ Disease Inadequately Controlled by Antithyroid Drugs

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:Efgartigimod Alfa
Sponsor:Argenx

Contact Research Centre

Colitis ulcerative

Recruiting

Long‑Term Safety and Efficacy of SPY001-001, SPY002 and SPY003 in Adults with Ulcerative Colitis

Investigational

Long‑Term Safety and Efficacy of SPY001-001, SPY002 and SPY003 in Adults with Ulcerative Colitis

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:SPY001-001
Sponsor:Spyre Therapeutics Inc.

Contact Research Centre

Other cities in Spain

The busiest research cities in the country

All 203 cities in Spain

Clinical research in Sevilla

What the registry says about research in the country

01 Metabolic and Endocrine Disorders

Innovative research focusing on Type 1 Diabetes management and weight-related conditions, evaluating new therapeutic approaches for glycemic control and metabolic health.

Diabetes Management
Obesity Treatment
Metabolic Disorders

Studies aim to improve treatment outcomes for patients with complex metabolic conditions.

02 Neurological Conditions

Advanced clinical trials examining treatments for Multiple Sclerosis and neurodegenerative disorders, including pioneering research in Frontotemporal Dementia and Parkinson's disease.

Multiple Sclerosis Therapies
Neurodegenerative Diseases
Brain Health Innovation

Research focuses on developing targeted treatments for various neurological conditions.

03 Infectious Diseases

Comprehensive vaccine development programs targeting Influenza, Cytomegalovirus, and meningococcal infections, with emphasis on preventive medicine.

Vaccine Development
Viral Infections
Immunization Studies

Studies aim to enhance vaccine efficacy and immune response across different age groups.

04 Oncology Research

Groundbreaking studies in cancer treatment, including research on bladder cancer and mantle cell lymphoma, exploring combination therapies and targeted treatments.

Cancer Immunotherapy
Targeted Therapies
Combination Treatments

Focus on developing innovative approaches to improve cancer treatment outcomes.

05 Autoimmune Conditions

Clinical investigations into Psoriatic Arthritis and inflammatory conditions, evaluating novel therapeutic approaches and treatment combinations.

Arthritis Treatment
Inflammatory Diseases
Immune System Disorders

Research aims to develop more effective treatments for chronic autoimmune conditions.

Back to Spain All countries